Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 36.79%35.53B | 28.61%32.52B | -10.40%17.02B | 36.41%115.88B | 7.47%45.64B | 22.41%25.97B | 53.44%25.28B | 296.60%18.99B | 81.69%84.95B | 45.56%42.47B |
| Net income from continuing operations | 38.22%21.19B | 34.70%18.16B | 64.19%17.13B | 94.73%59.25B | 88.29%20B | 55.16%15.33B | 99.78%13.49B | 228.85%10.43B | 1,217.74%30.43B | 3,721.58%10.62B |
| Depreciation and amortization | 24.95%16.8B | 26.49%15.23B | 22.06%14.26B | 8.49%52.8B | 13.10%15.63B | 10.81%13.44B | 3.87%12.04B | 5.04%11.68B | 16.08%48.66B | 8.95%13.82B |
| Remuneration paid in stock | -9.11%4.85B | -2.80%6.53B | -25.64%3.69B | -8.38%22.01B | -20.95%5B | -8.51%5.33B | -5.68%6.72B | 4.49%4.96B | 22.44%24.02B | 12.72%6.32B |
| Deferred tax | 869.17%10.13B | 101.40%11M | 154.05%507M | 20.90%-4.65B | -9.84%-1.61B | -10.12%-1.32B | 71.39%-785M | -98.73%-938M | 27.88%-5.88B | 56.52%-1.46B |
| Other non cashItems | -7,071.63%-10.11B | -1,224.21%-1.26B | -203.04%-2.82B | 368.98%2.01B | -43.36%-486M | 85.76%-141M | -302.13%-95M | 411.99%2.73B | -104.41%-748M | -109.84%-339M |
| Change In working capital | -9.72%-7.32B | -1.30%-6.16B | -59.39%-15.75B | -34.66%-15.54B | -47.43%7.1B | -50.45%-6.67B | 3.32%-6.08B | 30.97%-9.88B | 44.74%-11.54B | 28.30%13.51B |
| -Change in receivables | -182.03%-1.98B | 49.07%-1.13B | -66.15%1.25B | 61.08%-3.25B | 45.98%-4.02B | 80.44%-701M | -8.23%-2.21B | -22.02%3.68B | 3.18%-8.35B | -265.97%-7.45B |
| -Change in inventory | 45.20%-827M | -31.41%-4.05B | -168.81%-1.22B | -230.02%-1.88B | -64.66%934M | -286.76%-1.51B | -30.00%-3.09B | 378.71%1.78B | 155.90%1.45B | -16.89%2.64B |
| -Change in payables and accrued expense | 143.68%152M | 13.35%2.11B | 7.78%-13.1B | -97.77%68M | -26.96%12.77B | -123.22%-348M | 70.30%1.86B | 16.54%-14.21B | 119.54%3.05B | 11.86%17.48B |
| -Change in other current assets | 10.98%-4.04B | 2.75%-2.97B | -25.95%-3.4B | -18.08%-14.48B | -49.54%-4.19B | -44.77%-4.54B | 2.27%-3.06B | 15.67%-2.7B | 7.61%-12.27B | ---2.8B |
| -Change in other working capital | -250.12%-632M | -129.24%-119M | -53.57%728M | -12.47%4.01B | -55.61%1.61B | 1,784.00%421M | 160.90%407M | 91.69%1.57B | 106.59%4.58B | 618.61%3.63B |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 36.79%35.53B | 28.61%32.52B | -10.40%17.02B | 36.41%115.88B | 7.47%45.64B | 22.41%25.97B | 53.44%25.28B | 296.60%18.99B | 81.69%84.95B | 45.56%42.47B |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -54.29%-26.07B | -78.08%-39.42B | -66.85%-29.8B | -89.32%-94.34B | -197.14%-37.44B | -43.78%-16.9B | -128.86%-22.14B | -13.01%-17.86B | -32.53%-49.83B | -16.45%-12.6B |
| Net PPE purchase and sale | -60.86%-34.23B | -91.35%-31.37B | -74.06%-24.26B | -61.34%-77.66B | -95.10%-26.05B | -88.33%-21.28B | -57.44%-16.39B | -6.62%-13.94B | 17.47%-48.13B | 13.52%-13.35B |
| Net business purchase and sale | -26.37%-786M | -197.72%-1.7B | 101.43%48M | -21.29%-7.08B | -565.35%-2.54B | 61.82%-622M | -80.70%-571M | 4.53%-3.35B | 29.79%-5.84B | 54.15%-381M |
| Net investment purchase and sale | 78.78%8.94B | -22.84%-6.36B | -876.61%-5.6B | -331.99%-9.6B | -881.64%-8.86B | 325.98%5B | -590.43%-5.17B | -173.75%-573M | -85.75%4.14B | -79.21%1.13B |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -54.29%-26.07B | -78.08%-39.42B | -66.85%-29.8B | -89.32%-94.34B | -197.14%-37.44B | -43.78%-16.9B | -128.86%-22.14B | -13.01%-17.86B | -32.53%-49.83B | -16.45%-12.6B |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 98.40%-44M | 43.45%-2.54B | 96.26%-47M | 25.61%-11.81B | 50.96%-3.31B | 69.18%-2.76B | 31.34%-4.49B | -119.77%-1.26B | -263.40%-15.88B | -7,944.19%-6.75B |
| Net issuance payments of debt | 101.42%38M | 43.45%-2.54B | 96.26%-47M | 25.61%-11.81B | 48.80%-3.56B | 69.83%-2.68B | 31.34%-4.49B | -119.77%-1.26B | -201.02%-15.88B | -8,174.42%-6.94B |
| Net common stock issuance | ---- | ---- | ---- | --0 | ---- | ---- | ---- | --0 | --0 | ---- |
| Net other financing activities | -5.13%-82M | ---- | ---- | ---- | ---- | -21.88%-78M | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 98.40%-44M | 43.45%-2.54B | 96.26%-47M | 25.61%-11.81B | 50.96%-3.31B | 69.18%-2.76B | 31.34%-4.49B | -119.77%-1.26B | -263.40%-15.88B | -7,944.19%-6.75B |
| Net cash flow | ||||||||||
| Beginning cash position | -14.26%61.45B | -4.69%69.89B | 11.40%82.31B | 36.20%73.89B | 57.10%78.68B | 43.15%71.67B | 47.45%73.33B | 36.20%73.89B | 48.73%54.25B | 42.36%50.08B |
| Current changes in cash | 49.00%9.41B | -601.41%-9.45B | -9,849.61%-12.84B | -49.45%9.72B | -78.87%4.89B | 1,123.64%6.31B | -610.23%-1.35B | 97.23%-129M | 1.93%19.23B | 25.38%23.12B |
| Effect of exchange rate changes | -157.54%-397M | 423.08%1.01B | 196.97%416M | -422.83%-1.3B | -280.90%-1.25B | 237.45%690M | -552.17%-312M | -395.86%-429M | 136.87%403M | 8.48%691M |
| End cash Position | -10.44%70.46B | -14.26%61.45B | -4.69%69.89B | 11.40%82.31B | 11.40%82.31B | 57.10%78.68B | 43.15%71.67B | 47.45%73.33B | 36.20%73.89B | 36.20%73.89B |
| Free cash from | -87.17%430M | -95.67%332M | -296.95%-8B | 2.05%32.88B | -36.14%17.8B | -61.65%3.35B | 52.58%7.66B | 143.15%4.06B | 290.71%32.22B | 121.58%27.88B |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.